TG Therapeutics TGTX Other Research And Development Expense
Other Research And Development Expense at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's other research and development expense?
- TG Therapeutics (TGTX) reported other research and development expense of $43.52M in Q1 2026.
- How has TG Therapeutics's other research and development expense changed year-over-year?
- TG Therapeutics's other research and development expense increased by 1.1% year-over-year, from $43.03M to $43.52M.
- What is the long-term trend for TG Therapeutics's other research and development expense?
- Over 4 years (2021 to 2025), TG Therapeutics's other research and development expense has grown at a -7.8% compound annual growth rate (CAGR), from $198.53M to $143.6M.
- What does other research and development expense mean?
- General cash-based expenses related to the company's research and development efforts.
- How do you interpret other research and development expense?
- An increase suggests accelerated investment in the product pipeline, which may lead to future growth but reduces current profitability.
- How does other research and development expense compare across companies?
- Varies significantly by industry; biotech companies typically have high R&D intensity compared to service firms.